Successful Treatment of Secukinumab-Resistant Palmoplantar Pustulosis by Dupilumab: A Case Report.
Yu-Xin Zheng,Min Zheng,Sui-Qing Cai
DOI: https://doi.org/10.1111/dth.15781
2022-01-01
Dermatologic Therapy
Abstract:Dermatologic TherapyVolume 35, Issue 11 e15781 LETTER Successful treatment of secukinumab-resistant palmoplantar pustulosis by Dupilumab: A case report Yu-Xin Zheng, Yu-Xin Zheng Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorMin Zheng, Min Zheng Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorSui-Qing Cai, Corresponding Author Sui-Qing Cai [email protected] Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China Correspondence Sui-Qing Cai, Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China. Email: [email protected]Search for more papers by this author Yu-Xin Zheng, Yu-Xin Zheng Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorMin Zheng, Min Zheng Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorSui-Qing Cai, Corresponding Author Sui-Qing Cai [email protected] Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China Correspondence Sui-Qing Cai, Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China. Email: [email protected]Search for more papers by this author First published: 20 August 2022 https://doi.org/10.1111/dth.15781 Funding information: This study was funded by the grant from the National Natural Science Foundation of China (NFSC) (82073426). Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Misiak-Galazka M, Zozula J, Rudnicka L. Palmoplantar Pustulosis: recent advances in Etiopathogenesis and emerging treatments. Am J Clin Dermatol. 2020; 21(3): 355-370. 2Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017; 389(10086): 2287-2303. 3Mrowietz U, Bachelez H, Burden AD, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study. J Am Acad Dermatol. 2019; 80(5): 1344-1352. 4Avallone G, Cariti C, Dapavo P, et al. Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis. J Eur Acad Dermatol Venereol. 2022; 36(7):e574-e576. 5Brumfiel CM, Patel MH, Zirwas MJ. Development of psoriasis during treatment with dupilumab: a systematic review. J Am Acad Dermatol. 2021; 86(3): 708-709. 6Russo F, Provvidenziale L, Bruzziches F, et al. Psoriasis-like eruption triggered by Dupilumab therapy. Dermatitis. 2021; 32(6): e147-e148. 7Safa G, Paumier V. Psoriasis induced by dupilumab therapy. Clin Exp Dermatol. 2019; 44(3): e49-e50. 8McCluskey D, Benzian-Olsson N, Mahil SK, et al. Single-cell analysis implicates Th17 to Th2 cell plasticity in the pathogenesis of palmoplantar pustulosis. J Allergy Clin Immunol. 2022;S0091-6749(22)00624-8. Volume35, Issue11November 2022e15781 ReferencesRelatedInformation